NEW YORK (GenomeWeb) – OpGen announced today that it has signed a supply agreement with Thermo Fisher Scientific to combine its Acuitas Rapid Test for Pathogen ID with Thermo Fisher's real-time PCR solutions.

The deal is intended to help support the commercialization of OpGen's rapid molecular products and informatics system to help combat multidrug-resistant infections, the company said. Combining genomic analysis with bioinformatics can help healthcare providers efficiently and accurately identify bacterial antibiotic susceptibility, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.